Karo Pharma divests brand portfolio to Evolan Pharma
prnewswire.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.co.uk Daily Mail and Mail on Sunday newspapers.
Jämtlands bryggeri firar 25 år: Förhoppningsvis kan vi ha någon festlighet till hösten
ltz.se - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from ltz.se Daily Mail and Mail on Sunday newspapers.
Så här kan nationalsångens krigiska andra vers skrivas om
dn.se - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from dn.se Daily Mail and Mail on Sunday newspapers.
Karo Pharma acquires European OTC brand portfolio from Teva Pharmaceuticals
News provided by
Share this article
Share this article
HUDDINGE, Sweden, Feb. 3, 2021 /PRNewswire/ Karo Pharma Aktiebolag ( Karo ) today announces the acquisition of an OTC brand portfolio containing Flux
®, Decubal
The transaction transfers ownership of the brand portfolio, comprised of Flux
®, Decubal
® and Fludent
® from Teva to Karo. The brands generated sales just short of EUR 35m in 2020 on a global basis. The majority is generated in the Nordic markets, including Scandinavia, where the brands already are distributed and marketed by Karo under a 7-year license agreement that was signed in the spring of 2019.